Medulloblastoma natural history: Difference between revisions
Jump to navigation
Jump to search
| Line 18: | Line 18: | ||
* The 5-year survival rate of patients with medulloblastoma is approximately 69%.<ref name="wiki">Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September 25, 2015</ref> | * The 5-year survival rate of patients with medulloblastoma is approximately 69%.<ref name="wiki">Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September 25, 2015</ref> | ||
* The 10-year survival rate of patients with medulloblastoma is approximately 52%. | * The 10-year survival rate of patients with medulloblastoma is approximately 52%. | ||
* Younger age of | * Younger age of children is associated with worse prognosis.<ref name="pmid9869216">{{cite journal| author=Saran FH, Driever PH, Thilmann C, Mose S, Wilson P, Sharpe G et al.| title=Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. | journal=Int J Radiat Oncol Biol Phys | year= 1998 | volume= 42 | issue= 5 | pages= 959-67 | pmid=9869216 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9869216 }} </ref> | ||
* The prognosis varies with the molecular subgroup of medulloblastoma, such as:<ref name="wiki">Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September 25, 2015</ref> | * The prognosis varies with the molecular subgroup of medulloblastoma, such as:<ref name="wiki">Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September 25, 2015</ref> | ||
:* Medulloblastoma ''WNT'' molecular subgroup is associated with the most favorable prognosis. | :* Medulloblastoma ''WNT'' molecular subgroup is associated with the most favorable prognosis. | ||
Revision as of 14:24, 5 October 2015
|
Medulloblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Medulloblastoma natural history On the Web |
|
American Roentgen Ray Society Images of Medulloblastoma natural history |
|
Risk calculators and risk factors for Medulloblastoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
If left untreated, patients with medulloblastoma may progress to develop ataxia, nystagmus, and positional dizziness. Common complications of medulloblastoma include hydrocephalus, decerebrate attacks, and cranial nerve palsies. Prognosis is generally good, the 5-year survival rate of patients with medulloblastoma is approximately 69%.[1]
Natural History
- Most patients with medulloblastoma are initially asymptomatic. If left untreated, most of the patients with medullblastoma will develop ataxia, nystagmus, and positional dizziness within a few months.[1]
Complications
- Common complications of medulloblastoma include:[1]
- Increased intracranial pressure
- 3rd, 4th, and 6thcranial nerve palsy
- Decerebrate attacks
Prognosis
- Medulloblastoma prognosis is generally good.
- The 5-year survival rate of patients with medulloblastoma is approximately 69%.[1]
- The 10-year survival rate of patients with medulloblastoma is approximately 52%.
- Younger age of children is associated with worse prognosis.[2]
- The prognosis varies with the molecular subgroup of medulloblastoma, such as:[1]
- Medulloblastoma WNT molecular subgroup is associated with the most favorable prognosis.
- Medulloblastoma Group 4 and SHH molecular subgroups are associated with an intermediate prognosis.
- Medulloblastoma Group 3 molecular subgroup is associated with a poor prognosis.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Medulloblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Medulloblastoma Accessed on September 25, 2015
- ↑ Saran FH, Driever PH, Thilmann C, Mose S, Wilson P, Sharpe G; et al. (1998). "Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation". Int J Radiat Oncol Biol Phys. 42 (5): 959–67. PMID 9869216.